NRX Pharmaceuticals- Warrants (24/05/2026) Operating Income

As of the most recent data (June 2026), NRXPW shows a operating income of $-20M. That compares with $-13M in the prior-year period — down 52.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NRXPW's operating income is now $-20M (was $-13M) — a 52.4% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether NRX Pharmaceuticals- Warrants (24/05/2026) is outperforming or lagging.

Tracking NRXPW's operating income over time shows whether NRX Pharmaceuticals- Warrants (24/05/2026) is scaling, shrinking, or reshaping that part of the business. The current reading is $-20M That compares with $-13M in the prior-year period — down 52.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has NRX Pharmaceuticals- Warrants (24/05/2026)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-20M) with ownership activity and broader fundamentals.

NRX Pharmaceuticals- Warrants (24/05/2026)'s operating income is $-20M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.